Gwalrus Biomaterials announces successful completion of nearly 100 million Series B financing to establish leadership in bio-based material synthesis and application

Recently, Gwalrus Biomaterials announced the successful completion of an approximately 100 million Series B financing round. This round was exclusively invested by Jiazhi Fund, with WinX Capital acting as the financial advisor to Gwalrus Biomaterials and continuing to oversee subsequent financing activities. As another significant capital move following the investment from the CTHG Fund, this latest financing will provide strong momentum for Gwalrus Biomaterials' core technology development, capacity expansion, and market exploration, supporting the company in achieving leapfrog development within the bio-based materials sector. Meanwhile, Gwalrus Biomaterials is actively preparing for a Series B+ financing round.

As a national high-tech enterprise and a Shanghai-certified specialized and sophisticated SME, Gwalrus Biomaterials has been dedicated to closed-loop innovation in "AI + Synthetic Biology + Bio-based Materials" since its founding in 2020. Leveraging biomanufacturing technologies, Gwalrus Biomaterials has established green, low-carbon super cell factories and built a comprehensive industrial chain covering "non-food biomass → lactic acid → lactide → PLA → products → rPLA recycling." This integrated production system spans "material synthesis to industrial application," setting a benchmark for green transformation and high-quality development in the industry.

With cutting-edge R&D capabilities, Gwalrus Biomaterials has mastered multiple internationally advanced production technologies across the entire bio-based materials industrial chain. Key breakthroughs include "non-food biomass utilization," "next-generation industrial strains," "gypsum-free lactic acid technology," and "rPLA recycling," positioning its technical capabilities on par with leading global counterparts. Among these, the "gypsum-free lactic acid technology" addresses the industry challenge of massive gypsum solid waste generated during traditional lactic acid production, enabling cleaner and lower-cost lactic acid manufacturing. Meanwhile, the chemically-based "rPLA recycling" process not only enables closed-loop recycling of polylactic acid (PLA) at the same quality level, effectively reducing production costs, but also establishes a full lifecycle circular system for PLA products—from production and application to recycling—contributing to the sustainable development of the bio-based materials industry.

Gwalrus Biomaterials' core product, polylactic acid (PLA), is a high-performance bio-based biodegradable material known for its excellent biocompatibility, degradability, and processability. It is widely used in fast-moving consumer goods, food and beverage packaging, agriculture, 3D printing, textile fibers, biomedicine, high-end manufacturing, and other fields. Supported by its full industrial chain layout, Gwalrus Biomaterials maintains end-to-end control from raw material supply to bio-based material production and recycling. This not only ensures consistent product quality but also provides significant cost advantages and market competitiveness, offering customers integrated bio-based material solutions.

The funds raised in this round will primarily be allocated to expanding production capacity at Gwalrus Biomaterials' large-scale production base, advancing R&D and iteration of next-generation technologies, and expanding market channels. It is reported that Gwalrus Biomaterials has already achieved phased milestones in the industrialization of bio-based materials, with steadily growing production capacity and market share. This financing round will further accelerate Gwalrus Biomaterials' scaling process and reinforce its leadership position in the industry.